Swiss National Bank Has $1.51 Million Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Swiss National Bank boosted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERVFree Report) by 13.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 108,500 shares of the company’s stock after buying an additional 13,200 shares during the quarter. Swiss National Bank owned approximately 0.17% of Verve Therapeutics worth $1,512,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Teacher Retirement System of Texas boosted its stake in shares of Verve Therapeutics by 10.8% during the third quarter. Teacher Retirement System of Texas now owns 12,058 shares of the company’s stock valued at $160,000 after purchasing an additional 1,174 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Verve Therapeutics by 18.0% during the third quarter. Principal Financial Group Inc. now owns 16,847 shares of the company’s stock valued at $223,000 after purchasing an additional 2,566 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Verve Therapeutics by 5.6% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 16,479 shares of the company’s stock valued at $219,000 after purchasing an additional 871 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Verve Therapeutics by 9.3% during the third quarter. Arizona State Retirement System now owns 12,343 shares of the company’s stock valued at $164,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Jump Financial LLC acquired a new stake in shares of Verve Therapeutics during the third quarter valued at about $357,000. 97.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VERV has been the topic of a number of recent research reports. Stifel Nicolaus cut their price target on Verve Therapeutics from $56.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Verve Therapeutics in a research note on Thursday, May 9th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $35.00 price objective on shares of Verve Therapeutics in a research report on Wednesday, February 28th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Verve Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Check Out Our Latest Stock Analysis on VERV

Verve Therapeutics Price Performance

Shares of VERV opened at $5.28 on Tuesday. Verve Therapeutics, Inc. has a 1 year low of $5.23 and a 1 year high of $21.42. The company has a market capitalization of $443.31 million, a price-to-earnings ratio of -1.84 and a beta of 1.94. The business has a 50-day moving average of $7.98 and a 200-day moving average of $11.27.

Verve Therapeutics (NASDAQ:VERVGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.11. The business had revenue of $5.70 million during the quarter, compared to the consensus estimate of $2.11 million. Verve Therapeutics had a negative return on equity of 37.35% and a negative net margin of 1,226.51%. Verve Therapeutics’s revenue was up 305.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Verve Therapeutics, Inc. will post -2.73 EPS for the current year.

Insiders Place Their Bets

In other Verve Therapeutics news, insider Andrew D. Ashe bought 76,000 shares of the stock in a transaction on Tuesday, May 14th. The stock was acquired at an average cost of $6.26 per share, for a total transaction of $475,760.00. Following the completion of the acquisition, the insider now owns 342,509 shares in the company, valued at approximately $2,144,106.34. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 19.30% of the stock is currently owned by corporate insiders.

About Verve Therapeutics

(Free Report)

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

Read More

Institutional Ownership by Quarter for Verve Therapeutics (NASDAQ:VERV)

Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.